Close Menu

South Korean FDA

The company will now initiate the dose escalation portion of a Phase I/II study and will enroll 90 NSCLC patients in the country.

The drug is designed to tackle C797S resistance mutations that arise in NSCLC patients after treatment with third-generation tyrosine kinase inhibitors.